1Kayagaki N,Kawasaki A,Ebata T,et al.Metalloproteinase-mediated release of human Fas ligand[ J].J Exp Med,1995,182(6):1777 -1783.
2Tanaka M,Suda T,Takahashi T,et al.Expression of the functional soluble form of human Fas ligand in activated lymphocytes[ J ].EMBO J,1995,14(6):1129-1135.
3Tanaka M,Suda T,Yatomi T,et al.Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes[ J].J Immunol,1997,158(5):2303-2309.
4Cheng J,Zhou T,Liu C,et al.Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule[J].Science,1994,263(5154):1759-1762.
5Cascico I,Fiucci G,Papoff G,et al.Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing[J].J Immunol,1995,154(6):2706-2713.
6Hughes D P,Crispe I N.A naturally occurring soluble isoform of murine Fas generated by alternative splicing[J].J Exp Med,1995,182(5):1395 -1401.
7Jodo S,Kobayashi S,Nakajima Y,et al.Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma[J].Clin Exp Immunol,1998,112(2):166 -171.
8Midis G P,Shun Y,Owen Schaub L B.Elevated soluble Fas (sFas)levels in nonhematopoietic human malignancy[ J].Cancer Res,1996,56(17):3870 -3873.
9Suda T,Tanaka M,Miwa K,et al.Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand[J].J Immunol,1996,157(9):3918 -3924.
10Golstein P,Marguet D,Depraetere V.Fas bridging cell death and cytotoxicity:the reaper connection[J] Immunol Rev,1995,146:45-56.
7[2]Muschen M,Moers C,Warskulat U,et al.CD95 ligand expression in dedifferentiated breast cancer.Pat hol,1999,189(3):378-386.
8[3]TanakaM,Suda T,Yatomi T,et al.Lethal effect of recombinant human Fas ligand in mice pretreated with Prop ionibacterium acnes.Immunol,1997,158(5):2303-2309.
9Neragi-Miandoab S. Malignant pleural effusion, current and evol- ving approaches for its diagnosis and management. Lung Cancer, 2006,54( 1 ) :1-9.
10Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res, 1999,5 ( 11 ) :3529- 3533.
